MX2021005364A - Metodos y composiciones que comprenden polipeptidos recombinantes purificados. - Google Patents

Metodos y composiciones que comprenden polipeptidos recombinantes purificados.

Info

Publication number
MX2021005364A
MX2021005364A MX2021005364A MX2021005364A MX2021005364A MX 2021005364 A MX2021005364 A MX 2021005364A MX 2021005364 A MX2021005364 A MX 2021005364A MX 2021005364 A MX2021005364 A MX 2021005364A MX 2021005364 A MX2021005364 A MX 2021005364A
Authority
MX
Mexico
Prior art keywords
methods
purified recombinant
compositions
recombinant polypeptides
polypeptides
Prior art date
Application number
MX2021005364A
Other languages
English (en)
Inventor
Martin Vanderlaan
X Christopher Yu
Susan C Fisher
John Lowe
Atia Naim
Ailen M Sanchez
Christopher A Teske
Annamarie Amurao
Jayme Franklin
Saloumeh Kadkhodayan Fischer
Corazon Victa
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2021005364A publication Critical patent/MX2021005364A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan polipéptidos recombinantes purificados aislados de células huésped de ovario de hámster chino, incluyendo anticuerpos tales como anticuerpos terapéuticos y métodos de preparación y uso de tales polipéptidos.
MX2021005364A 2013-09-13 2016-03-10 Metodos y composiciones que comprenden polipeptidos recombinantes purificados. MX2021005364A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361877517P 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
MX2021005364A true MX2021005364A (es) 2021-06-30

Family

ID=52666315

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016003202A MX2016003202A (es) 2013-09-13 2014-09-12 Metodos y composiciones que comprenden polipeptidos recombinantes purificados.
MX2021005358A MX2021005358A (es) 2013-09-13 2016-03-10 Metodos y composiciones que comprenden polipeptidos recombinantes purificados.
MX2021005364A MX2021005364A (es) 2013-09-13 2016-03-10 Metodos y composiciones que comprenden polipeptidos recombinantes purificados.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2016003202A MX2016003202A (es) 2013-09-13 2014-09-12 Metodos y composiciones que comprenden polipeptidos recombinantes purificados.
MX2021005358A MX2021005358A (es) 2013-09-13 2016-03-10 Metodos y composiciones que comprenden polipeptidos recombinantes purificados.

Country Status (18)

Country Link
US (7) US9920120B2 (es)
EP (3) EP3683232A1 (es)
JP (4) JP6751344B2 (es)
KR (2) KR102571391B1 (es)
CN (1) CN105722532A (es)
AR (2) AR097651A1 (es)
AU (2) AU2014318615B2 (es)
BR (1) BR112016004413A2 (es)
CA (2) CA2921999C (es)
HK (1) HK1225988A1 (es)
IL (1) IL244149A0 (es)
MX (3) MX2016003202A (es)
MY (2) MY193481A (es)
NZ (3) NZ756750A (es)
RU (1) RU2671481C2 (es)
SG (2) SG10201802525QA (es)
WO (1) WO2015038888A1 (es)
ZA (4) ZA201601965B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145208A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Hydrophobic interaction protein chromatography under no-salt conditions
NZ756750A (en) * 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
TW201702380A (zh) 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
CA2995385A1 (en) * 2015-08-20 2017-02-23 Genentech, Inc. Purification of fkpa and uses thereof for producing recombinant polypeptides
CN107835819A (zh) * 2015-08-21 2018-03-23 豪夫迈·罗氏有限公司 在亲和层析中减少宿主细胞蛋白的方法
CN116063375A (zh) * 2015-08-21 2023-05-05 豪夫迈·罗氏有限公司 在亲和层析中减少宿主细胞蛋白的方法
CN115109148A (zh) * 2016-04-14 2022-09-27 隆扎有限公司 用于检测宿主细胞蛋白的组合物和方法
EP3487868B1 (en) * 2016-07-25 2024-08-28 Cephalon, Inc. Affinity chromatography wash buffer
IL264631B2 (en) 2016-08-16 2024-05-01 Regeneron Pharma A method for quantifying individual antibodies from a mixture
DK3510042T3 (da) 2016-09-07 2024-06-10 Glaxosmithkline Ip Dev Ltd Fremgangsmåde til rensning af antistoffer
JP7471819B2 (ja) 2016-10-06 2024-04-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 工程不純物への結合が低下している抗体
SG11201902667UA (en) 2016-10-25 2019-05-30 Regeneron Pharma Methods and systems for chromatography data analysis
HRP20221071T1 (hr) 2016-12-23 2022-11-11 Serum Institute Of India Private Limited Postupci za povećanje produktivnosti antitijela u kulturi stanica sisavaca i smanjenje agregacije tokom nizvodne obrade, postupci formulacije i rezultirajuće stabilne formulacije antitijela
SG11202001564QA (en) 2017-09-19 2020-04-29 Regeneron Pharma Methods of reducing particle formation and compositions formed thereby
TW202003555A (zh) * 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
US11884698B2 (en) 2018-07-02 2024-01-30 Regeneron Pharmaceuticals, Inc. Systems and methods for preparing a polypeptide from a mixture
US20220267369A1 (en) * 2018-07-25 2022-08-25 Merck Sharp & Dohme Corp. Methods of separating host cell lipases from a production protein in chromatographic processes
KR20210118815A (ko) 2019-01-23 2021-10-01 다이이찌 산쿄 가부시키가이샤 활성탄 재료를 사용하는 공정을 포함하는 항체 정제 방법
WO2020157749A1 (en) * 2019-01-29 2020-08-06 Bnai Zion Medical Center Anti il-17 antibody for use in treating chronic spontaneous urticaria
US20220314142A1 (en) * 2019-07-01 2022-10-06 Pfizer Inc. Improvements to wash solutions for protein a chromatography in an antibody purification process
WO2021064079A1 (en) * 2019-10-04 2021-04-08 Merck Patent Gmbh Purification of proteins and viral inactivation
US20230077205A1 (en) * 2020-01-29 2023-03-09 Merck Sharp & Dohme Llc Methods of separating host cell lipases from an anti-lag3 antibody production
CA3216037A1 (en) * 2021-05-03 2022-11-10 Agilent Technologies, Inc. Chimeric immunogens and methods for making polyclonal antibodies against specific epitopes
WO2023215750A2 (en) * 2022-05-02 2023-11-09 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity
WO2024137702A1 (en) * 2022-12-19 2024-06-27 Eli Lilly And Company Methods of reducing contaminants in protein purification
CN117169518B (zh) * 2023-11-03 2024-01-19 赛德特(北京)生物工程有限公司 T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3645090A (en) 1969-06-19 1972-02-29 Citizen Watch Co Ltd Day-date quick-adjuster for calender timepiece
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3422247A1 (de) 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Gluco-oligosaccharid-gemisch und verfahren zu seiner herstellung
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US4847745A (en) 1988-11-16 1989-07-11 Sundstrand Corp. Three phase inverter power supply with balancing transformer
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5011778A (en) 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
IL96714A0 (en) 1989-12-20 1991-09-16 Schering Corp Antibody antagonists of human interleukin-4
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
HU217099B (hu) 1991-03-29 1999-11-29 Elf Sanofi Sa. Eljárás citokin típusú aktivitással rendelkező fehérje, azt kódoló rekombináns DNS-szekvencia és a megfelelő transzformált sejtek és mikroorganizmusok előállítására
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5994514A (en) 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
US5965709A (en) 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
WO1993015766A1 (en) 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens
WO1993016177A1 (en) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
AU680816B2 (en) 1992-05-15 1997-08-14 Quest International B.V. Cloning and expression of DNA encoding a ripening form of a polypeptide having phamnogalacturonase activity
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
CA2142860A1 (en) 1992-08-21 1994-03-03 Gregorio Aversa Human interleukin-13
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
CA2160458A1 (en) 1993-05-17 1994-11-24 Thomas G. Warner Cho cell sialidase by recombinant dna technology
ATE188487T1 (de) 1993-09-02 2000-01-15 Dartmouth College Anti-gp39 antikoerper und deren verwendungen
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6911530B1 (en) 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
AU718899C (en) 1995-10-23 2004-01-29 Amrad Operations Pty. Limited A novel haemopoietin receptor and genetic sequences encoding same
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
CN103275221B (zh) 1996-02-09 2016-08-17 艾伯维生物技术有限公司 结合人TNFα的人抗体
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US7078494B1 (en) 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
AU6450196A (en) 1996-06-12 1998-01-07 Human Genome Sciences, Inc. Hr-1 receptor
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
DE69739673D1 (de) 1996-11-27 2009-12-31 Genentech Inc Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix
US6743604B1 (en) 1996-12-13 2004-06-01 Smithkline Beecham Corporation Substances and their uses
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
TR199902191T2 (xx) 1997-01-10 1999-12-21 Biogen, Inc. Anti-CD40L bile�ikleri ile lupus nefritis tedavisi
US6132730A (en) 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment
US6576232B1 (en) 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
US6482403B1 (en) 1998-05-29 2002-11-19 Heska Corporation Caniney IL-13 immunoregulatory proteins and uses thereof
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
GB9820014D0 (en) 1998-09-14 1998-11-04 Cancer Res Campaign Tech Receptor antagonists and uses thereof
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
DE19848026A1 (de) 1998-10-17 2000-04-20 Bayer Ag Verfahren zur Herstellung von Bis(4-hydroxyaryl)alkanen
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
BR9916209A (pt) 1998-12-14 2001-12-26 Genetics Inst Cadeia de receptor de citocina
AU2750800A (en) 1999-02-01 2000-08-18 Amgen Canada Inc. Materials and methods to inhibit hodgkin and reed sternberg cell growth
WO2001034645A2 (en) 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Mutated il-13 molecules and their uses
US20100041039A1 (en) 2000-01-15 2010-02-18 Synageva Biopharma Corp. Analysis of nucleic acid obtained from nucleated red blood cells
SK288711B6 (sk) 2000-02-24 2019-11-05 Univ Washington Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok
US6989145B2 (en) 2000-03-03 2006-01-24 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody and antibody fragment
CN1323812A (zh) 2000-05-16 2001-11-28 上海博德基因开发有限公司 一种新的多肽——人白细胞介素－13(il－13)受体11和编码这种多肽的多核苷酸
AU1091802A (en) 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded agonist antibody
JP2004537500A (ja) 2000-10-20 2004-12-16 ジェネティクス インスティテュート，エルエルシー 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1345967B1 (en) 2000-12-22 2011-08-10 Grad, Carole, Legal representative of Kaplan, Howard Phage display libraries of human v h fragments
WO2003002144A1 (en) 2001-06-26 2003-01-09 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
US20030023555A1 (en) 2001-07-26 2003-01-30 Cashworks, Inc. Method and system for providing financial services
MXPA04001894A (es) 2001-08-31 2005-09-08 Kyowa Hakko Kogyo Kk Anticuerpo humano injertado en una cdr y fragmento de dicho anticuerpo.
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20040023337A1 (en) 2001-10-26 2004-02-05 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
DK1443960T3 (da) 2001-11-07 2009-03-23 Cytos Biotechnology Ag Antigen-arrays der betegner IL-5, IL-13 eller eotaxin til behandling af allergiske eosinofile sygdomme
CA2473144C (en) 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
WO2003086451A1 (en) 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
US20040060102A1 (en) 2002-04-10 2004-04-01 Interspiro, Inc. Garments for biological, chemical and fire protection
ES2545067T3 (es) 2002-04-26 2015-09-08 Genentech, Inc. Purificación de proteínas basada en la no afinidad
EP1552462B1 (en) 2002-06-14 2011-03-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods of treating and preventing colitis involving il-13 and nk-t cells
JP2006503017A (ja) 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド Ｉｌ−１３要素及びｔ細胞エピトープを含む免疫原組成物並びにその治療上の使用
EP1534329A2 (en) 2002-08-30 2005-06-01 Glaxo Group Limited Vaccine comprising il-13 and an adjuvant
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
WO2004071408A2 (en) 2003-02-10 2004-08-26 Applied Molecular Evolution, Inc. Aβ BINDING MOLECULES
US7157276B2 (en) 2003-06-20 2007-01-02 Biogen Idec Inc. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
PT1639011E (pt) 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
CN104013957B (zh) 2003-12-23 2016-06-29 泰勒公司 用新的抗il13单克隆抗体治疗癌症
PT1704166E (pt) 2004-01-07 2015-09-04 Novartis Vaccines & Diagnostic Anticorpo monoclonal específico de m-csf e respetivos usos
US20080261249A1 (en) 2004-01-13 2008-10-23 Genentech, Inc Detecting and Quantifying Host Cell Proteins in Recombinant Protein Products
BRPI0509495A2 (pt) 2004-02-06 2016-10-11 Nymox Corp anticorpo humanizado
JP4851348B2 (ja) 2004-02-23 2012-01-11 イーライ リリー アンド カンパニー 抗Ａβ抗体
US20070037966A1 (en) * 2004-05-04 2007-02-15 Novo Nordisk A/S Hydrophobic interaction chromatography purification of factor VII polypeptides
WO2005111225A1 (en) 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag O-linked glycoforms of polypeptides and method to manufacture them
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
NZ554520A (en) 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
NZ555986A (en) 2004-12-24 2008-12-24 Commw Scient Ind Res Org Fumigant pesticide compositions and methods of applying
CN104610422A (zh) 2005-03-11 2015-05-13 惠氏公司 弱分配层析的方法
KR20080006601A (ko) 2005-04-11 2008-01-16 메다렉스, 인코포레이티드 단백질 정제 방법
KR101247836B1 (ko) 2005-06-17 2013-03-28 와이어쓰 엘엘씨 항 ａ 베타 항체의 정제 방법
JP3982545B2 (ja) 2005-09-22 2007-09-26 ダイキン工業株式会社 空気調和装置
JP2009510046A (ja) * 2005-09-30 2009-03-12 メドイミューン・リミテッド インターロイキン−１３抗体組成物
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
US7667557B2 (en) 2005-12-06 2010-02-23 Tdk Corporation Thin-film bandpass filter using inductor-capacitor resonators
KR20150098683A (ko) 2005-12-12 2015-08-28 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
NZ568241A (en) 2005-12-12 2011-08-26 Hoffmann La Roche Antibodies against amyloid beta 4 with glycosylation in the variable region
ES2382164T3 (es) 2005-12-30 2012-06-05 Merck Patent Gmbh Anticuerpos anti-IL-6 que impiden la unión de la IL-6 en complejo con el IL-6R( ) a la GP130
US7563875B2 (en) 2006-03-20 2009-07-21 The United States of America as represented by the Sercretary of the Army Recombinant chimeric human anti-botulinum antibodies
RU2466740C2 (ru) * 2006-04-05 2012-11-20 Эбботт Байотекнолоджи Лтд. Очистка антитела
MX2008013394A (es) 2006-04-21 2008-10-31 Wyeth Corp Metodos para tamizado de alta emision de lineas celulares.
SG173385A1 (en) 2006-07-14 2011-08-29 Ac Immune S A Ch Humanized antibody against amyloid beta
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
MX2009003034A (es) 2006-09-21 2009-11-18 Verenium Corp Fosfolipasas, acidos nucleicos que las codifican, y metodos de hacerlas y usarlas.
PL2074145T3 (pl) 2006-10-02 2017-11-30 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
KR101551984B1 (ko) 2006-10-04 2015-09-09 제넨테크, 인크. Ｖｅｇｆ용 ｅｌｉｓａ
US8383350B1 (en) 2006-12-20 2013-02-26 Merck Sharp & Dohme Corp. Assay for detection of IL-10 antibodies
JP5419709B2 (ja) 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
WO2008140455A1 (en) 2007-05-15 2008-11-20 Tanox, Inc. Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies
RU2567151C2 (ru) 2007-06-12 2015-11-10 Ац Иммуне С.А. Гуманизированные антитела к амилоиду бета
CL2008001742A1 (es) 2007-06-12 2008-11-21 Ac Immune Sa Anticuerpo monoclonal que reconoce un epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos; polinucleotido que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados a proteinas amiloides.
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
AU2008311366B2 (en) 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
SG185277A1 (en) 2007-10-05 2012-11-29 Genentech Inc Humanized antibody
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
WO2009058769A1 (en) * 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
EP2631302A3 (en) 2008-03-31 2014-01-08 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
WO2009131643A1 (en) 2008-04-21 2009-10-29 Monabio, Inc. Immunoassay for specific determination of s-adenosymethionine and analogs thereof in biological samples
US20090317400A1 (en) 2008-05-05 2009-12-24 Krzysztof Masternak Anti-IL 17A/IL-17F Cross-Reactive Antibodies and Methods of Use Thereof
PL2322221T3 (pl) 2008-08-05 2015-01-30 Toray Industries Kompozycja farmaceutyczna do leczenia i zapobiegania raka
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
GB0818674D0 (en) 2008-10-10 2008-11-19 Univ Bath Materials and methods for resolving polyhydric species by electrophoresis
KR20110093799A (ko) 2008-10-20 2011-08-18 아보트 러보러터리즈 Ｉｌ-12에 결합하는 항체 및 이의 정제 방법
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
JP2012506239A (ja) 2008-10-20 2012-03-15 アボット・ラボラトリーズ Ｉｌ−１８に結合する抗体およびそれを精製する方法
SG10201702951RA (en) 2008-10-20 2017-06-29 Abbvie Inc Viral inactivation during purification of antibodies
CN101979404B (zh) 2008-12-09 2015-01-14 厦门大学 H5亚型禽流感病毒保守中和表位模拟肽及其用途
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
WO2011010940A1 (en) 2009-07-19 2011-01-27 Serguei Zavtrak Solar electric power generator
BR112012002574A2 (pt) 2009-08-06 2020-11-03 Genentech, Inc. método para aprimorar a remoção de vírus na purificação de proteínas
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
UA109884C2 (uk) 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
LT3037104T (lt) * 2009-10-20 2020-09-10 Abbvie Inc. Anti-il-13 antikūnų izoliavimas ir gryninimas, naudojant afininę baltymo a chromatografiją
DK3342786T3 (en) 2010-01-29 2021-09-27 Chugai Pharmaceutical Co Ltd Anti-dll3-antistof
GEP201706660B (en) 2010-03-04 2017-04-25 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
SG185583A1 (en) 2010-05-17 2012-12-28 Livtech Inc Anti-human trop-2 antibody having antitumor activity in vivo
HRP20171095T4 (hr) 2010-05-25 2022-07-22 F. Hoffmann - La Roche Ag Postupci pročišćavanja polipeptida
AR082194A1 (es) 2010-07-06 2012-11-21 Aveo Pharmaceuticals Inc Anticuerpos anti-ron
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
EA201390467A1 (ru) 2010-09-29 2013-11-29 Дженентек, Инк. Композиции антител и способы применения
PT2646470T (pt) * 2010-11-30 2017-05-03 Hoffmann La Roche Anticorpos anti-recetor da transferrina de baixa afinidade e a sua utilização na transferência de scfv terapêuticos através da barreira hematoencefálica
CA2817380C (en) 2010-12-16 2019-06-04 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
CN103608040B (zh) 2011-04-20 2017-03-01 米迪缪尼有限公司 结合b7‑h1和pd‑1的抗体和其他分子
FI3091029T3 (fi) * 2011-10-31 2023-03-20 Hoffmann La Roche Anti-il13-vasta-aineformulaatioita
EP2773439A4 (en) * 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR DECOMPOSING HETEROGENEOUS ANTIBODY AGGREGATES
TW201326193A (zh) * 2011-11-21 2013-07-01 Genentech Inc 抗－ｃ－ｍｅｔ抗體之純化
WO2013089477A1 (en) 2011-12-15 2013-06-20 Hanwha Chemical Corporation A method of antibody purification
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
CN107184974A (zh) 2012-02-29 2017-09-22 吉利德生物制剂公司 抗基质金属蛋白酶9的抗体
ES2915378T3 (es) * 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
NZ756750A (en) * 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides

Also Published As

Publication number Publication date
BR112016004413A2 (pt) 2017-10-17
KR20160052724A (ko) 2016-05-12
ZA202101142B (en) 2022-09-28
ZA201601965B (en) 2018-11-28
US20180273615A1 (en) 2018-09-27
MY176026A (en) 2020-07-22
CA2921999C (en) 2023-03-21
US20210115126A1 (en) 2021-04-22
US10597446B2 (en) 2020-03-24
JP7489953B2 (ja) 2024-05-24
SG10201802525QA (en) 2018-04-27
ZA201801849B (en) 2021-07-28
NZ718144A (en) 2022-05-27
EP4331605A3 (en) 2024-05-22
AU2020200502B9 (en) 2022-03-24
JP2022036971A (ja) 2022-03-08
US20180312585A1 (en) 2018-11-01
CA3184564A1 (en) 2015-03-19
JP2016539176A (ja) 2016-12-15
AR097651A1 (es) 2016-04-06
RU2016108828A3 (es) 2018-05-29
AU2020200502A1 (en) 2020-02-13
JP6751344B2 (ja) 2020-09-02
US20180291094A1 (en) 2018-10-11
RU2016108828A (ru) 2017-10-18
JP2019178139A (ja) 2019-10-17
EP3043820A1 (en) 2016-07-20
AU2014318615A9 (en) 2016-06-16
CA2921999A1 (en) 2015-03-19
EP3043820A4 (en) 2017-07-12
US20230250165A1 (en) 2023-08-10
KR102571391B1 (ko) 2023-08-29
EP3683232A1 (en) 2020-07-22
US9920120B2 (en) 2018-03-20
US10597447B2 (en) 2020-03-24
WO2015038888A9 (en) 2016-03-17
AU2014318615A1 (en) 2016-04-21
MY193481A (en) 2022-10-17
JP2024059617A (ja) 2024-05-01
AR118560A2 (es) 2021-10-20
KR102373930B1 (ko) 2022-03-11
KR20220034930A (ko) 2022-03-18
US20160319012A1 (en) 2016-11-03
HK1225988A1 (zh) 2017-09-22
US10494429B2 (en) 2019-12-03
IL244149A0 (en) 2016-04-21
JP6982027B2 (ja) 2021-12-17
MX2021005358A (es) 2021-06-30
US20180291095A1 (en) 2018-10-11
EP4331605A2 (en) 2024-03-06
CN105722532A (zh) 2016-06-29
US10822404B2 (en) 2020-11-03
AU2020200502B2 (en) 2022-03-10
SG11201601823TA (en) 2016-04-28
NZ756749A (en) 2022-05-27
NZ756750A (en) 2022-05-27
RU2671481C2 (ru) 2018-10-31
US11667706B2 (en) 2023-06-06
WO2015038888A1 (en) 2015-03-19
AU2014318615B2 (en) 2020-03-12
ZA202201361B (en) 2023-11-29
MX2016003202A (es) 2016-06-07

Similar Documents

Publication Publication Date Title
ZA202201361B (en) Methods and compositions comprising purified recombinant polypeptides
MX2015011951A (es) Proteinas de fusion que comprenden partes de union a pdgf y vegf y metodos de uso de las mismas.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
IN2014MN02518A (es)
IN2014DN08481A (es)
MX2024008825A (es) Composicion para la estimulacion ovarica controlada.
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX2017003211A (es) Anticuerpos anti-met y composiciones.
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
MX2018014043A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
IL243627A0 (en) Pharmaceutical preparations of pancreatin with high potency
IL284419A (en) Pharmaceutical preparations of pancreatin with high potency
MX2016005285A (es) Conjugados de somatostatina y sus analagos.
MX2015012905A (es) Formulaciones de factor viii recombinantes.
MX2021009154A (es) Selectividad eficaz de proteinas recombinantes.